Amil Družić, Oncology and Radiotherapy Resident at the Clinical Center University of Sarajevo, shared a post by OncoDaily on LinkedIn, adding:
“It was a real privilege to be among the distinguished faculty of the OncoDaily
‘How I Treat Head and Neck Cancers in 2026’ Virtual Summit, where I delivered the lecture:
‘HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Current Standards and What We Have Learned From De-escalation Trials.’
The central message is clear: in HPV-associated oropharyngeal cancer, cure remains the first priority. De-escalation is not simply about giving less treatment; it is about identifying, with precision, which patients can safely receive the right amount of treatment while preserving excellent oncologic outcomes.
Current evidence reminds us to be cautious. Some shortcuts, such as replacing cisplatin with cetuximab in eligible patients, have failed. Definitive radiation dose reduction remains investigational for many patients. The most promising directions are risk-adapted postoperative strategies, pathology-guided treatment, PET- and biomarker-based selection, and carefully designed clinical trials.
As the field moves forward, the goal should not be ‘less therapy’ for its own sake. The goal is the least toxic treatment that still protects cure, function, and long-term quality of life.”
Highlights From How I Treat Head and Neck Cancers in 2026: OncoDaily Virtual Summit.
Other Articles Featuring Amil Družić on OncoDaily.